Synonyms: ETC-159 | ETC159 | ETC1922159
Compound class:
Synthetic organic
Comment: ETC-1922159 (ETC-159) is an orally bioavailable, clinical stage porcupine inhibitor [1-3]. It is being developed for oncology potential.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Ho SY, Alam J, Jeyaraj DA, Wang W, Lin GR, Ang SH, Tan ESW, Lee MA, Ke Z, Madan B et al.. (2017)
Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors. J Med Chem, 60 (15): 6678-6692. [PMID:28671458] |
2. Ho SY, Blanchard, SE, Duraiswamy AJ, Alam J, Adsool VA. (2014)
Purine diones as Wnt pathway modulators. Patent number: WO2014189466A1. Assignee: Agency For Science, Technology And Research. Priority date: 23/05/2013. Publication date: 27/11/2014. |
3. Ho SY, Keller TH. (2015)
The use of porcupine inhibitors to target Wnt-driven cancers. Bioorg Med Chem Lett, 25 (23): 5472-6. [PMID:26522946] |
4. Madan B, Ke Z, Harmston N, Ho SY, Frois AO, Alam J, Jeyaraj DA, Pendharkar V, Ghosh K, Virshup IH et al.. (2016)
Wnt addiction of genetically defined cancers reversed by PORCN inhibition. Oncogene, 35 (17): 2197-207. [PMID:26257057] |